Servier Canada
Asparlas®
ASPARLAS logo; ASPARLAS calaspargase pegol for injection

Comparative product overview

Select parameters for ASPARLAS®, ONCASPAR®, and RYLAZE™

ASPARLAS®

calaspargase pegol for injection1

Indication in ALL

ASPARLAS® is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients age 1 to 21 years.

Half-life

16.1 days IV infusion1

Half-life based on PK data after a single dose of ASPARLAS® 2500 IU/m2

Recommended dose

2500 U/m2 IV no more than every 21 days1

Shelf life

Proposed shelf life of 36 months. Store ASPARLAS® refrigerated at 2°C to 8°C in the original carton to protect from light. Do not shake or freeze product. Unopened vials may be stored at room temperature (15°C to 25°C) for no more than 48 hours. Diluted solution may be stored for up to 4 hours at room temperature (15°C to 25°C) or refrigerated at 2°C to 8°C for up to 24 hours. Discard any unused portion left in a vial.

Data from separate Product Monographs and regulatory documents; comparative clinical significance has not been proven.

Consult the individual Product Monographs for complete dosing and administration information.

Dosing protocols for ASPARLAS®*, ONCASPAR®†, and RYLAZE™‡

Asparaginase

Week 1

ASPARLAS®1

ONCASPAR®3

or

RYLAZE™5

*The recommended dose of ASPARLAS® is 2500 U/m2 IV no more than every 21 days.
†The recommended dose of ONCASPAR® for patients with BSA >0.6 m2 and aged ≤21 years is 2500 U (equivalent to 3.3 mL ONCASPAR®)/m² body surface area IV or IM every 14 days.
‡The recommended dosage of RYLAZE™ is 25 mg/m2 on Monday and Wednesday and 50 mg/m2 IM on Friday, for a total of six doses to replace each planned dose of pegaspargase.

= intravenous infusion

= intramuscular

Data from separate Product Monographs; comparative clinical significance has not been proven.

See individual Product Monographs for complete dosing and administration information.

Learn more about Servier Canada’s treatment options in ALL

Learn more

Consult the ASPARLAS® Product Monograph

Learn more

aBFM: augmented Berlin-Frankfurt-Münster; AE: adverse event; ALL: acute lymphoblastic leukemia; ALP: alkaline phosphatase; ALT: alanine aminotransferase; aPTT: activated partial thromboplastin time; AST: aspartate aminotransferase; BFM: Berlin-Frankfurt-Munster; BSA: body surface area; CSF: cerebrospinal fluid; CTCAE: Common Terminology Criteria for Adverse Events; DFCI: Dana-Farber Cancer Institute; IM: intramuscular; IV: intravenous; NCCN: National Comprehensive Cancer Network®; NPAA: nadir plasma arparaginase activity; NSAA: nadir serum asparaginase activity; NSAID: non-steroidal anti-inflammatory drug; PD: pharmacodynamics; PK: pharmacokinetics; TDM: therapeutic drug monitoring.

* Comparative clinical significance has not been established.

† Fictitious cases. May not be representative of all patients.

‡ Clinical significance has not been established.

References:

  1. ASPARLAS® Product Monograph. Servier Canada.
  2. Data on file. Servier Canada.
  3. ONCASPAR® Product Monograph. Servier Canada.
  4. RYLAZE™ Product Monograph. Jazz Pharmaceuticals Canada Inc.
  5. Government of Canada. Summary Basis of Decision for Asparlas. Available at https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1718207489396.
  6. Government of Canada. ONCASPAR_CPID Redacted.
  7. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577.
  8. Mank V, Azhar W, Brown K. Leukocytosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; April 21, 2024.
  9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute Lymphoblastic Leukemia, version 4.2023 – February 05, 2024.
  10. Vrooman LM et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: Results of DFCI 11-001. J Clin Oncol. 2021;39(31):3496–3505.
  11. National Institutes of Health. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE): Version 4.0. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5×11.pdf. Accessed December 11, 2024.
Back to top

Stay Connected with Servier Canada

Stay up to date on disease information, treatment options, our products, and patient support programs.

Sign Up